

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

**UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE FIRST QUARTER ENDED 31 OCTOBER 2023⁽¹⁾**

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	31.10.2023	31.10.2022	31.10.2023	31.10.2022
	RM'000	RM'000	RM'000	RM'000
Revenue	14,524	11,314	14,524	11,314
Cost of sales	(9,859)	(7,483)	(9,859)	(7,483)
Gross profit	4,665	3,831	4,665	3,831
Other income	507	522	507	522
Marketing expenses	(273)	(232)	(273)	(232)
Administrative and other expenses	(2,222)	(1,784)	(2,222)	(1,784)
Finance costs	(51)	(89)	(51)	(89)
Profit before tax	2,626	2,248	2,626	2,248
Taxation	(531)	(247)	(531)	(247)
Profit for the financial period,	2,095	2,001	2,095	2,001
Other comprehensive income, net of tax	-	-	-	-
Total comprehensive income	2,095	2,001	2,095	2,001
Profit attributable to:				
Owners of the parent	1,889	2,001	1,889	2,001
Non-controlling interests	206	-	206	-
	2,095	2,001	2,095	2,001
Earnings per share attributable to owners of the parent ("EPS"):				
Basic and diluted ⁽²⁾ (sen)	0.51	0.54	0.51	0.54

Notes:

- (1) The basis of preparation of the Unaudited Consolidated Statement of Profit or Loss and Other Comprehensive Income is disclosed in Note A1 and should be read in conjunction with the Group's Audited Financial Statements for the financial year ended 31 July 2023 and the accompanying explanatory notes attached to this interim financial report.
- (2) Diluted EPS is equivalent to the basic EPS as there were no potential dilutive securities in issue during the financial period under review.

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 OCTOBER 2023⁽¹⁾

	Unaudited as at 31 October 2023 RM'000	Audited as at 31 July 2023 RM'000
ASSETS		
Non-current assets		
Property, plant and equipment	25,007	24,370
Right-of-use assets	4,776	4,810
Deferred tax assets	-	-
Goodwill	287	287
Current assets		
Inventories	11,183	12,514
Trade and other receivables	17,494	12,799
Marketable securities	10,471	11,874
Current tax assets	806	525
Derivative assets	6	6
Cash and bank balances	6,718	6,107
TOTAL ASSETS	76,748	73,292
EQUITY AND LIABILITIES		
Equity		
Share capital	44,348	44,348
Reserves	20,536	18,647
Equity attributable to owners of the parent	64,884	62,995
Non-controlling interest	688	482
TOTAL EQUITY	65,572	63,477
Non-current liabilities		
Borrowings	2,826	2,877
Lease liabilities	7	7
Government grants	2,873	2,873
Deferred tax liabilities	305	307
Current liabilities		
Trade and other payables	3,811	2,583
Borrowings	584	711
Lease liabilities	31	44
Government grants	278	370
Current tax liabilities	461	43
TOTAL LIABILITIES	11,176	9,815
TOTAL EQUITY AND LIABILITIES	76,748	73,292

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 OCTOBER 2023⁽¹⁾ (cont'd)

Note:

- (1) The basis of preparation of the Unaudited Consolidated Statement of Financial Position is disclosed in Note A1 and should be read in conjunction with the Group's Audited Financial Statements for the financial year ended 31 July 2023 and the accompanying explanatory notes attached to this interim financial report.

UMediC Group Berhad
 (Company No. 202101015347) (1415647-D)
 (Incorporated in Malaysia under the Companies Act 2016)

UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE FIRST QUARTER ENDED 31 OCTOBER 2023⁽¹⁾

	Attributable to owners of the Parent						
	Non-distributable		Distributable		Total	Non-controlling interest	Total equity
	Share capital	Reorganisati on debit reserve	Retained earnings				
	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	
Balance as at 1 August 2023	44,348	(6,851)	25,498	62,995	482	63,477	
Profit for the financial year	-	-	1,889	1,889	206	2,095	
Other comprehensive income, net of tax	-	-	-	-	-	-	
Total comprehensive income	-	-	1,889	1,889	206	2,095	
Balance as at 31 Oct 2023	44,348	(6,851)	27,387	64,884	688	65,572	

Note:

- (1) The basis of preparation of the Unaudited Consolidated Statement of Changes in Equity is disclosed in Note A1 and should be read in conjunction with the Group Audited Financial Statements for the financial year ended 31 July 2023 and the accompanying explanatory notes attached to this interim financial report.

(The remaining of this page is intentionally left blank)

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

**UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOW FOR THE FIRST QUARTER ENDED
31 OCTOBER 2023⁽¹⁾**

	3-month ended 31 October 2023 RM'000	3-month ended 31 October 2022 RM'000
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit before tax	2,626	2,248
Adjustments for:		
Depreciation of property, plant and equipment	578	471
Depreciation of right-of-use assets	34	31
Amortisation of government grants	(92)	(92)
Finance costs	51	89
Interest income	(48)	(17)
Distribution income from short-term fund	(97)	(7)
Property, plant and equipment written off	3	(2)*
Realised gain on fair value adjustment on marketable securities	-	(5)
Unrealised gain on foreign exchange	(144)	(5)
Unrealised gain on fair value adjustment on marketable securities	-	(117)
Operating profit before changes in working capital	2,911	2,596
Decrease/(Increase) in inventories	1,331	(1,673)
Increase in trade and other receivables	(4,695)	(4,409)
Increase in trade and other payables	1,225	4,089
Cash generated from operations	772	603
Interest received	48	17
Tax paid	(566)	(524)
Tax refunded	169	-
Net cash from operating activities	423	96
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of marketable securities	(1,000)	-
Purchase of property, plant and equipment	(1,218)	(700)
Proceeds from disposal of marketable securities	2,500	1,000
Net cash from investing activities	282	300

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

**UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE FOURTH QUARTER ENDED
31 OCTOBER 2023⁽¹⁾ (Cont'd)**

	3-month ended 31 October 2023	3-month ended 31 October 2022
	RM'000	RM'000
CASH FLOWS FROM FINANCING ACTIVITIES		
Drawdown of bankers' acceptance	-	1,500
Repayment of bankers' acceptance	-	(2,950)
Repayment of term loans	(178)	(246)
Interest paid	(51)	(89)
Payment of lease liabilities	(13)	(10)
Net cash used in financing activities	(242)	(1,795)
Net increase/(decrease) in cash and cash equivalents	463	(1,399)
Effect of foreign exchange rates changes	147	5
Cash and cash equivalents at beginning of financial year	6,108	4,160
Cash and cash equivalents at end of financial period	<u>6,718</u>	<u>2,766</u>

Notes:

* Represent less than RM1,000.

(1) The basis of preparation of the Unaudited Consolidated Statement of Cash Flows is disclosed in Note A1 and should be read in conjunction with the Group's Audited Financial Statements for the financial year ended 31 July 2023 and the accompanying explanatory notes attached to this interim financial report.

(2) There is property, plant and equipment written off amounting to RM564.

(The remaining of this page is intentionally left blank)

A. NOTES TO THE INTERIM FINANCIAL REPORT

A1. Basis of preparation

The interim financial report of UMediC Group Berhad (“**UMC**” or the “**Company**”) and its subsidiaries (collectively, the “**Group**”) is unaudited and has been prepared in accordance with Malaysian Financial Reporting Standard (“**MFRS**”) 134, Interim Financial Reporting issued by the Malaysian Accounting Standards Board (“**MASB**”) and Rule 9.22 of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad (“**Bursa Securities**”) (“**Listing Requirements**”).

This interim financial report should be read in conjunction with the Group’s Audited Financial Statements for the financial year ended 31 July 2023 and the accompanying explanatory notes attached to this interim financial report.

A2. Significant Accounting Policies

The significant accounting policies and methods of computation applied in the unaudited condensed financial statements are consistent with those adopted in audited financial statements for the financial year ended 31 July 2023, except for the adoption of the following MFRSs and Amendment to MFRSs and Interpretation.

(a) New MFRSs adopted during the financial period

The Group and the Company adopted the following Standards of the MFRS Framework that were issued by the MASB during the financial periods:

Title	Effective Date
Annual Improvements to MFRS Standards 2018 - 2020	1 January 2022
Amendments to MFRS 3 <i>Reference to the Conceptual Framework</i>	1 January 2022
Amendments to MFRS 116 <i>Property, Plant and Equipment – Proceeds before Intended Use</i>	1 January 2022
Amendments to MFRS 137 <i>Onerous Contract - Cost of Fulfilling a Contract</i>	1 January 2022
MFRS 17 <i>Insurance Contracts</i>	1 January 2023
Amendment to MFRS 17 <i>Insurance Contracts</i>	1 January 2023
Amendment to MFRS 17 <i>Initial Application of MFRS 17 and MFRS 9 - Comparative Information</i>	1 January 2023
Amendments to MFRS 101 <i>Disclosure of Accounting Policies</i>	1 January 2023
Amendments to MFRS 108 <i>Definition of Accounting Estimates</i>	1 January 2023
Amendments to MFRS 112 <i>International Tax Reform - Pillar Two Model Rules</i>	Refer MFRS112 Paragraph 98M
Amendments to MFRS 112 <i>Deferred Tax related to Assets and Liabilities arising from a Single Transaction</i>	1 January 2023

Adoption of the above Amendments to Standards did not have any material effect on the financial performance or position of the Group and of the Company.

(b) New MFRSs that have been issued, but only effective for annual periods beginning on or after 1 January 2023

Title	Effective Date
Amendment to MFRS 16 <i>Lease Liability in a Sale and Leaseback</i>	1 January 2024
Amendments to MFRS 101 <i>Classification of Liabilities as Current or Non-current</i>	1 January 2024
Amendments to MFRS 101 <i>Non-current Liabilities with Covenants</i>	1 January 2024
Amendments to MFRS 107 <i>Supplier Finance Arrangements</i>	1 January 2024
Amendments to MFRS 112 <i>Lack of Exchangeability</i>	1 January 2025
Amendments to MFRS 10 and MFRS 128 <i>Sale or Contribution of Assets between an Investor and its Associate or Joint Venture</i>	Deferred

The Group and the Company are in the process of assessing the impact of implementing these Standards and Amendments to Standards, since the effects would only be observable for the future financial years.

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

A3. Auditors' Report

There was no qualification on the audited financial statements of the Group for the financial year ended 31 July 2023.

A4. Seasonal or Cyclical Factors

The business operations of the Group were not affected by any seasonal or cyclical trend during the current quarter and financial period under review.

A5. Material Unusual Items

There were no unusual items affecting the assets, liabilities, equity, net income or cash flows of the Group during the current quarter and financial period under review.

A6. Material Changes in Estimates

There were no changes in estimates that have a material effect in the current quarter and financial period under review.

A7. Debt and Equity Securities

There was no issuance, cancellation, repurchase, resale and repayment of debts and equity securities during the current quarter and financial period under review.

A8. Dividend Paid

No dividend was paid during the current quarter.

A9. Segmental Information

The Group is principally involved in investment holding. Through its subsidiaries, the Group is principally involved in marketing and distribution of various branded medical devices and consumables as well as the provision of after-sales service for all its products. The Group is also involved in developing, manufacturing and marketing of its medical consumables.

For management purposes, the Group is organised into business units based on its products and services. The reportable segments of the Group are as follows:

(a) Marketing and distribution – marketing and distribution of medical devices as well as the provision of after-sales service; and

(b) Manufacturing – developing, manufacturing and marketing of medical consumables.

The Group's segmental information for the financial period under review is as follows:

31 October 2023	Manufacturing	Marketing and distribution	Eliminations	Consolidated
	RM'000	RM'000	RM'000	RM'000
Results				
Revenue from external customers	4,416	10,108	-	14,524
Inter-segment revenue	318	-	(318)	-
Total revenue	<u>4,734</u>	<u>10,108</u>	<u>(318)</u>	<u>14,524</u>
Interest income and distribution income from short-term fund	36	110	-	146
Interest expense	(8)	(47)	4	(51)
Net Interest income	<u>28</u>	<u>63</u>	<u>4</u>	<u>95</u>
Segment profit before tax	1,154	1,468	4	2,626

A10. Material Events Subsequent to the end of the Quarter

Save as disclosed in Note B6 on the Status of Corporate Proposals, there were no other material events subsequent to the end of the current quarter and financial period under review that have not been reflected in this interim financial report.

A11. Changes in the Composition of the Group

There were no changes in the composition of the Group during the current quarter and financial period under review.

A12. Contingent Liabilities and Contingent Assets

There were no material contingent liabilities or contingent assets as at the date of this interim financial report.

A13. Material Capital Commitment

Save as disclosed below, as at 31 October 2023, the Group does not have any other material capital commitment:

	RM'000
Capital expenditure in respect of purchase of property, plant and equipment	
- Approved and contracted for	446
- Approved but not contracted for	7,170
Total	7,616

A14. Significant Related Party Transactions

There were no significant related party transactions during the current quarter.

A15. Derivative Financial Instruments

Derivatives

The Group has entered into forward foreign currency contracts with financial institutions due within 1 year to sell at contractual forward rates.

As at 31 October 2023, the Group's outstanding derivatives are as follow:

	Contract amount as at 31 Oct 2023		Fair value as at 31 July 2023
	USD'000	RM'000 equivalent	RM'000
Forward foreign currency contracts	180	816	810

A16. Fair Value of Financial Liabilities

There were no gains or losses arising from fair value changes of the Group's financial liabilities for the current quarter and financial period under review.

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS

B1. Review of Performance

	Individual Quarter 3-months ended		Cumulative Quarter 3-months ended	
	31 Oct 2023 (RM'000)	31 Oct 2022 (RM'000)	31 Oct 2023 (RM'000)	31 Oct 2022 (RM'000)
Revenue	14,524	11,314	14,524	11,314
Profit before tax ("PBT")	2,626	2,248	2,626	2,248
Profit for the financial period/year	2,095	2,001	2,095	2,001
Profit attributable to owners of the parent	1,889	2,001	1,889	2,001

The Group's revenue increased by approximately RM3.21 million or 28.37% from approximately RM11.31 million achieved in the corresponding quarter of the previous financial year to approximately RM14.52 million in the current quarter.

The PBT of the Group increased by approximately RM0.38 million or 16.81% from approximately RM2.25 million in the corresponding quarter of the previous financial year to approximately RM2.63 million in the current quarter.

The increase in revenue and PBT in the current quarter as compared to the corresponding quarter was contributed by both the marketing and distribution and manufacturing segments. The increase was mainly due to a higher demand for medical devices and consumables from both public and private hospitals as well as healthcare service providers. In addition, the increase in the Group's revenue was also contributed by the increase in the sale of its manufactured medical consumables, namely HydroX series prefilled humidifiers and AirdroX series inhaler spacers, with a better foreign exchange rate for the overseas revenue.

B2. Comparison with Immediate Preceding Quarter

	Individual Quarter 3-months ended			
	31 Oct 2023 (RM'000)	31 July 2023 (RM'000)	Differences	
			RM'000	%
Revenue	14,524	12,015	2,509	20.88
PBT	2,626	4,499	(1,873)	(41.63)
Profit for the financial period	2,095	3,407	(1,312)	(38.51)
Profit attributable to owners of the parent	1,889	3,371	(1,482)	(43.96)

The Group's revenue increased by approximately RM2.51 million or 20.88% from approximately RM12.02 million achieved in the immediate preceding quarter to approximately RM14.52 million in the current quarter. The increase in revenue was mainly derived from the increase orders from marketing and distribution segment.

Despite the increase in the Group's revenue, the Group's PBT decreased by approximately RM1.87 million or 41.63% from approximately RM4.50 million achieved in the immediate preceding quarter to approximately RM2.63 million in the current quarter. The decrease was mainly due to the lower GP as well as an increase in marketing expenses and administrative and other expenses of approximately RM0.11 million and RM0.70 million respectively as compared to the immediate preceding quarter.

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

B3. Prospects

As the Malaysian government's unwavering commitment and ongoing pursuit to enhance the nation's healthcare standards, UMC embraces optimism towards its future ahead, anchored by several growth catalysts which stem from the growing demand for healthcare facilities upgrades, healthcare tourism as well as the crucial need to address overcrowding of facilities, fortifying the Group's pivotal role in the ever-evolving healthcare landscape.

The Ministry of Health has allocated RM41.2 billion under the Budget 2024, which is one of the biggest increases in terms of allocation.. This represents a robust 13.5% increase against the previous year's allocation of RM36.3 billion and it further demonstrates the government's stance and resolute emphasis on improving the nation's quality of healthcare. Further the Group believes that it will be able to benefit over the coming financial periods.

Furthermore, according to BMI Research, the nation's healthcare expenditure which encompasses both public and private hospitals, is anticipated to experience an upward trend until year 2027. BMI Research has projected an impressive 5-year compound annual growth rate of 8.0% and 7.3% for public and private healthcare expenditure, respectively. This upward trajectory is expected to significantly boost the demand in the medium term. With UMC's strategic expansion into the laboratory segment through the acquisition of Patho Solutions (M) Sdn Bhd, the Group is expected to capitalise on its robust distribution networks and established presence thereby effectively widening its market reach within the medical industry.

Barring unforeseen circumstances, the Group maintains confident of its future growth trajectory.

B4. Profit Forecast

The Group did not issue any profit estimate, forecast, projection or internal targets in any public document.

B5. Taxation

The Group's taxation together with the comparison between the effective and statutory tax rates for the current quarter and financial period under review are as follows:

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	3-month ended 31 October 2023 RM'000	3-month ended 31 October 2022 RM'000	3-month ended 31 October 2023 RM'000	3-month ended 31 October 2022 RM'000
Income tax				
Current tax expenses based on profit for the financial period	512	371	512	371
Under/(over)provision of tax expense in prior year	21	-	21	-
Deferred tax				
Relating to origination and reversal of temporary differences	(2)	(124)	(2)	(124)
Under/(over)provision in prior years	-	-	-	-
Overall tax expenses	531	247	531	247
Effective tax rate (%)	20.22	10.99	20.22	10.99
Statutory tax rate (%)	24.00	24.00	24.00	24.00

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

B5. Taxation (Cont'd)

The Group's effective tax rate was at 20.22% for current financial period. The effective tax rate for current financial period was lower than the statutory tax rate of 24.00% mainly due to the following:

- (i) tax incentive enjoyed by its wholly-owned subsidiary, UWHM Sdn Bhd. UWHM Sdn Bhd is entitled to reinvestment allowance incentives under Schedule 7A, Income Tax Act 1967 for qualifying capital expenditure on the acquisition of machinery and equipment and;
- (ii) amortisation of grants, which was not subject to income tax.

B6. Status of Corporate Proposals

On 30 October 2023, Affin Hwang Investment Bank Berhad ("**Affin Hwang IB**"), on behalf of the board of directors of UMC ("**Board**"), announced that the Company proposes to undertake a special issue of up to 24,930,000 new ordinary shares in UMC ("**UMC Share(s)**" or "**Share(s)**") ("**Special Issue Shares**"), representing approximately 6.67% of the existing total number of issued shares of the Company, to Bumiputera investors to be identified and/or approved by the Ministry of International Trade and Industry ("**MITI**") at an issue price to be determined and announced later ("**Proposed Special Issue**").

Subsequently, on 14 November 2023, Affin Hwang IB, on behalf of the Board, announced that Bursa Securities had vide its letter dated 14 November 2023, approved the listing of and quotation for up to 24,930,000 Special Issue Shares to be issued pursuant to the Proposed Special Issue.

Saved as disclosed above, there were no corporate proposals announced and not completed as at the date of this interim financial report.

B7. Utilisation of Proceeds from the IPO

The gross proceeds from the IPO amounting to RM31.11 million is expected to be utilised in the following manner:

Details of the use of proceeds	Estimated timeframe for the use of proceeds upon listing ⁽¹⁾	Proposed Utilisation RM'000	Actual Utilisation RM'000	Percentage utilised %	Deviation	
					RM'000	%
Capital expenditure						
(i) Construction of new factory building	Within thirty (30) months	3,500	2,877	82.20	-	-
(ii) Setting up new marketing and distribution offices	Within thirty-six (36) months	6,800	-	-	-	-
		10,300	2,877	27.93	-	-
Repayment of bank borrowings ⁽²⁾	Within six (6) months	9,000	9,000	100.00	-	-
Working capital	Within thirty-six (36) months	8,662	8,662	100.00	-	-
Estimated listing expenses	Within two (2) months	3,150	3,150	100.00	-	-
Total		31,112	23,689			

Notes:

- (1) From the date of listing of the Company on the ACE Market of Bursa Securities on 26 July 2022.
- (2) Including lease liabilities owing to financial institutions.

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

B8. Group Borrowings and Debt Securities

The details of the Group's borrowings are as follows:

	3-month ended 31 October 2023 RM'000	Audited as at 31 July 2023 RM'000
Current liabilities		
Term loan	584	711
Bankers' acceptance	-	-
	584	711
Non-current liabilities		
Term loan	2,826	2,877
	2,826	2,877
Total borrowings	3,410	3,588

All the Group's borrowings are denominated in RM, secured and interest-bearing.

B9. Material Litigation

As at the date of this interim financial report, the Group is not engaged in any material litigation or arbitration proceedings, either as plaintiff or defendant, and the Directors are not aware of any proceedings pending or threatened against the Group, which may materially and adversely affect the financial position or business performance of the Group.

B10. Dividend

No dividend has been declared or recommended for the current quarter ended 31 October 2023.

B11. Earnings Per Share

The basic and diluted EPS for the current quarter and financial period are computed as follows:

	3-month ended 31 October 2023	3-month ended 31 October 2022
Profit attributable to the owners of the parent (RM'000)	1,889	2,001
Number of ordinary shares (unit) ('000)	373,910	373,910
Basic EPS ⁽¹⁾ (sen)	0.51	0.54
Diluted EPS ⁽²⁾ (sen)	0.51	0.54

Notes:

- (1) Basic EPS is calculated by dividing the profit attributable to owners of the parent by the number of ordinary shares outstanding during the financial period under review.
- (2) Diluted EPS is equivalent to the basic EPS as there were no potential dilutive securities in issue during the financial period under review.

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

(The remaining of this page is intentionally left blank)

B.12 Profit Before Tax

Profit before tax is arrived at after charging/(crediting):

	3-month ended 31 October 2023	3-month ended 31 October 2022
	RM'000	RM'000
Depreciation of property, plant and equipment	578	471
Depreciation of right-of-use assets	34	31
Amortisation of government grants	(92)	(92)
Finance costs	51	89
Interest income	(48)	(17)
Distribution income from short-term fund	(97)	(7)
Property, plant and equipment written off	3	(1)*
Realised gain on fair value adjustment on marketable securities	-	(5)
Unrealised gain on foreign exchange	(144)	(5)
Unrealised gain on fair value adjustment on marketable securities	-	(117)

Notes:

* Represent less than RM1,000.

(1) There is property, plant and equipment written off amounting to RM564.

Save as disclosed above, the other disclosure items pursuant to Note 16, of Appendix 9B of the Listing Requirements are not applicable.

BY ORDER OF THE BOARD
4 December 2023